People | January 04, 2026
Aarti Pharmalabs appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Subscribe To Our Newsletter & Stay Updated
